Trial Profile
A non randomized study of BPX-501 in pediatric patients with orphan inherited blood disorders in the haploidentical stem cell transplant setting clinical trial.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2017
Price :
$35
*
At a glance
- Drugs Rivogenlecleucel (Primary)
- Indications Blood dyscrasias
- Focus Therapeutic Use
- 20 Mar 2017 New trial record
- 13 Mar 2017 According to a Bellicum Pharmaceuticals media release, the company expects to finalize discussions with the FDA on the protocol of this trial in the second quarter of 2017.